Clostridium difficile (CDI)

Educational ExhibitTM: Helping Bring The First New Therapy to Segment in 30 Years

Optimer Pharmaceuticals was developing a new drug for the treatment of Clostridium difficile infections (CDI). Their new drug would be the first new entry into this marketing segment in nearly 30 years.  The Educational ExhibitTM assisted Optimer in this breaking into this well-established segment.

Through the development of a custom branded, data rich, disease-state program, the Educational ExhibitTM addressed all of the above points and more.

The program reached over 1,800 targeted clinicians at four national conferences. Due to the settled established nature of the CDI segment, audiences were appreciative of the new data and updated details on CDI outbreaks and varying global mutations that clinicians typically face.

Ulcerative Colitis (UC)

Educational ExhibitTM: Helping to Establish a Niche

Santarus was developing a product targeted at a niche between two existing standards of therapy. The company was focused in an area that could potentially provide aid to a large number of patients and secure the company a new segment in am an expanding market. Case Study – Uceris outlines how the Educational ExhibitTM helped to achieve the desired result.

Demonstrating the Impact of a Targeted Pre-Market Awareness Program

Community-Acquired Pneumonia (CAP)

Educational ExhibitTM: Driving Awareness of a Critical Issue

Cempra was developing a new drug to address a critical clinical issue, the increasing impact of resistance related to cases of Community-Acquired Pneumonia (CAP). With resistance rates being over 50% in many part of the world, the Educational ExhibitTM was employed to present current data and circumstances to a range of clinician audiences. Through a series of seven events, over 2,000 medical professionals toured the exhibit and viewed the latest data on CAP.